Aesthetics is thinking past the cheeks and lips. March congress data spotlighted hyaluronic acid studies for the temple, chin, and even the decolletage, reflecting a whole-face, whole-area approach to volume and balance.
March 2026 congress data highlighted hyaluronic acid filler studies for less-traditional areas, the temple, chin, and decolletage, reflecting a shift toward whole-face and whole-area treatment. Rather than chasing individual wrinkles, providers increasingly address structure and proportion across regions, though some uses remain investigational or outside current U.S. approvals.
Filler conversations once centered on lips and cheeks; in 2026 they increasingly span the whole face and beyond.
March congress posters put several less-discussed treatment areas in the spotlight.
Among the data presented at AMWC Monaco were controlled studies of hyaluronic acid products for the temple region and for chin augmentation, along with a skin-quality hyaluronic acid injectable studied for wrinkles in the decolletage. The throughline is structural and proportional: addressing volume loss in the upper face (temples), defining the lower face (chin), and extending skin-quality treatment to the chest, rather than treating isolated lines.
This reflects a broader philosophy of facial balancing, in which proportion and harmony across regions guide treatment more than spot-correcting wrinkles. Importantly, regulatory status varies by region and area: some uses, such as filler in the decolletage, have been the subject of safety discussions and are not necessarily FDA-approved in the United States, even where studied or approved elsewhere.
For consumers, the whole-face trend can produce more natural, harmonious results, but it also means more areas, more product, and more nuance, raising the stakes for provider skill and anatomical knowledge. Treating new areas, especially those near important vessels or off-label sites, demands extra caution. Patients benefit from understanding which areas are FDA-approved for a given product and discussing the rationale and risks region by region.
Watch for new regulatory filings seeking approval for additional treatment areas, and for evolving safety guidance, particularly around regions like the decolletage where off-label use has drawn scrutiny. For patients, the practical questions are whether a proposed area is an approved use for the chosen product, what the specific risks are, and how experienced the provider is in that anatomical region. Whole-face thinking is promising, but area-by-area diligence still applies.